

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL HOLDINGS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023 IN RELATION TO THE ISSUANCE OF MEDIUM TERM NOTES AND CORPORATE BONDS IN THE PRC

Reference is made to: (i) the announcement dated 23 June 2021 in relation to, among others, the completion of the issuance of the first tranche of medium term notes for the year of 2021 by China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly owned subsidiary of China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”); and (ii) the announcement of the Company dated 21 January 2022 in relation to, among others, the completion of the public issuance of the 2022 first tranche corporate bonds in the PRC by CR Pharmaceutical Holdings (the “**Announcement**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless stated otherwise herein.

In accordance with the relevant rules and regulations in the PRC and in connection with the issuance of the first tranche of medium term notes for the year of 2021 and the public issuance of the 2022 first tranche corporate bonds in the PRC, CR Pharmaceutical Holdings is required to disclose its most recent consolidated unaudited quarterly financial information on the websites of the Shanghai Stock Exchange and the Beijing Financial Assets Exchange. The unaudited financial statements of CR Pharmaceutical Holdings and its subsidiaries for the nine months ended 30 September 2023 (the “**Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings**”) are enclosed to this announcement for the Company’s shareholders’ information only. The Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings were prepared in Chinese and have been translated for publication in both English and Chinese. In the event of any inconsistency between the two versions, the Chinese version shall prevail.

In addition, the Unaudited Quarterly Financial Statements of CR Pharmaceutical Holdings have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustments during the course of auditing. Such financial information is limited to CR Pharmaceutical Holdings and its subsidiaries only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

By order of the Board
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Hong Kong, 31 October 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
BALANCE SHEET IN ACCORDANCE WITH
THE PRC STANDARDS SEPTEMBER 2023

Adjusted to denominated currency

Unit: RMB1

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Current assets:			Current liabilities:		
Monetary fund	362,147,487.41	707,909,869.06	Short-term borrowings	1,680,000,000.00	1,040,000,000.00
Held-for-trading financial assets	1,006,307,878.31	200,128,989.39	Held-for-trading financial liabilities	-	-
Derivative financial assets	-	-	Notes payable and accounts payable	-	-
Notes receivable	-	-	Including: Notes payable	-	-
Accounts receivable	-	-	Accounts payable	-	-
Financing receivables	-	-	Receipts in advance	-	-
Prepayment	(51,851.02)	-	Contract liabilities	-	-
Other receivables	22,782,812,507.34	23,437,221,578.24	Staff remuneration payable	19,378,650.98	46,091,509.86
Including: Interest receivable	-	-	Including: Wages payable	-	-
Dividends receivable	5,416,748,449.32	5,416,748,449.32	Benefits payable	-	-
Inventory	-	-	Taxation payable	3,822,800.65	2,454,171.63
Including: Raw materials	-	-	Including: Tax payable	3,822,800.65	-
Goods in stock (finished products)	-	-	Other payables	7,853,567,975.97	14,348,655,903.43
Contract assets	-	-	Including: Interest payable	74,932,461.92	-
Assets held for sale	-	-	Dividends payable	3,507,000,000.00	3,507,000,000.00
Non-current assets due within one year	-	-	Insurance contract liabilities	-	-
Other current assets	-	10,818,810.96	liabilities held for sale	-	-
			Non-current liabilities due within one year	2,310,652,679.55	1,103,983,630.89
			Other current liabilities	-	-
Total current assets	24,151,216,022.04	24,356,079,247.65	Total current liabilities	11,867,422,107.15	16,541,185,215.81
Non-current assets:			Non-current liabilities:		
Other debt investments	-	-	Long-term borrowings	6,211,237,320.45	2,220,000,000.00
Debt investments	-	-	Bonds payable	4,500,000,000.00	4,500,000,000.00
Long-term receivables	20,000,000.00	-	Long-term payables	-	-
Other equity instruments investments	-	-	Including: Long-term payables	-	-
Long-term equity investments	15,315,753,952.86	15,210,729,627.80	Special payables	-	-
Investment properties	-	-	Long-term employee remuneration payable	360,580,000.00	330,550,000.00
Other non-current financial assets	-	6,000,000.00	△Deferred revenue	-	-
Fixed assets	2,967,563.47	3,252,759.86	Estimated liabilities	-	-
Including: Disposal of fixed assets	3,532.35	-	Deferred income tax liabilities	32,247.35	32,247.35
Right-of-use assets	21,850,091.84	21,850,091.84	Lease liabilities	23,166,398.95	12,111,653.04
Construction in progress	-	-	Other non-current liabilities	-	-
Biological assets for production	-	-	Including: Special reserve	-	-
Oil and gas assets	-	-	Total non-current liabilities	11,095,015,966.75	7,062,693,900.39
Intangible assets	-	80,511.02	Total liabilities	22,962,438,073.90	23,603,879,116.20
Including: Land use right	-	-	Owners' equity (or shareholders' equity):		
Development expenses	-	-	Paid-in capital (equity)	15,000,000,000.00	15,000,000,000.00
Goodwill	-	-	State-owned capital	-	-
Long-term deferred expenses	-	-	Collective capital	-	-
Deferred income tax assets	329,076.78	329,076.78	Legal person capital	15,000,000,000.00	15,000,000,000.00
Other non-current assets	3,438,063.63	23,674,779.75	Including: State-owned legal person capital	15,000,000,000.00	15,000,000,000.00
Including: Contract assets	-	-	Collectively-owned legal person capital	-	-
			Individual's capital	-	-
			Foreign capital	-	-
			Other equity instruments	-	-
			Capital surplus	34,472,792.11	34,472,792.11
			Less: treasury shares	-	-
			Other comprehensive income	20,900,416.58	20,900,416.58
			Including: Differences on translation of foreign currency statements	-	-
Total non-current assets	15,364,338,748.58	15,265,916,847.05	Surplus reserves	823,024,266.76	823,024,266.76
			Special reserves	-	-
			Undistributed profits	674,719,221.27	139,719,503.05
			Total equity attributable to owners of the parent company	16,553,116,696.72	16,018,116,978.50
			△Minority interests	-	-
Total assets	39,515,554,770.62	39,621,996,094.70	Total owners' equity	16,553,116,696.72	16,018,116,978.50
			Total liabilities and owners' equity	39,515,554,770.62	39,621,996,094.70

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF PROFIT OR LOSS IN ACCORDANCE WITH THE
PRC STANDARDS SEPTEMBER 2023

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Operating revenue	–	–
Including: Revenue from principal businesses	–	–
Revenue from other businesses	–	–
II. Operating costs	–	–
Including: Costs for principal businesses	–	–
Costs for other businesses	–	–
Tax and surcharge	11,458.46	493,567.44
Selling expenses	–	–
Management expenses	84,862,827.80	70,435,156.48
Including: Entertainment expenses	172,871.30	70,594.85
Research and development expenses	10,673,556.31	9,966,621.87
Finance costs	123,653,009.69	433,451,341.49
Including: Interest expenses	282,911,759.43	180,289,259.48
Interest income	59,191,051.14	197,592,771.45
Net Loss from exchange (net gain is represented by “–”)	(101,338,467.50)	446,666,002.25
Other revenue	182,299.90	662,321.35
Gain from investment (loss is represented by “–”)	756,727,281.36	658,614,170.50
Including: Gains from investment in associates and joint ventures	101,364,325.06	90,335,494.70
Net gains from hedging exposure (loss is represented by “–”)	–	–

Item	Accumulated amount for the year	Amount for the corresponding period of last year
Add: gains from changes in fair values (loss is represented by “—”)	178,888.92	—
Impairment losses of assets	—	—
Loss on credit impairment	—	—
Gains from disposal of assets	—	—
III. Operating profits (loss is represented by “—”)	537,887,617.92	144,929,804.57
Add: Non-operating income	112,100.30	—
Including: Gains from exchanging non-monetary assets	—	—
Government subsidies	—	—
Less: Non-operating expenses	3,000,000.00	1,500,000.00
Including: Loss on exchanging non-monetary assets	—	—
IV. Total profits (total loss is represented by “—”)	534,999,718.22	143,429,804.57
Less: Income tax expenses	—	13,216,523.30
V. Net profits (net loss is represented by “—”)	534,999,718.22	130,213,281.27
Including: Net gains of the absorbed party before business combination under common control		
Net profits attributable to the owners of the parent company	534,999,718.22	130,213,281.27
* Gains and losses of minority interests	—	—
Profit attributable to holders of perpetual capital instruments	—	

Item	Accumulated amount for the year	Amount for the corresponding period of last year
VI. Other comprehensive income, net of tax	–	–
(I) Other comprehensive income that cannot be reclassified into profit and loss	–	–
Changes arising from remeasurement of defined benefit plan	–	–
Other comprehensive income that cannot be reclassified into profit or loss under the equity method	–	–
Changes in fair value of other equity instrument investments	–	–
(II) Other comprehensive income that may be reclassified to profit or loss	–	–
Other comprehensive income that may be reclassified to profit or loss under equity method	–	–
Change in fair value of other debt investments	–	–
Amount included in other comprehensive income on reclassification of financial assets	–	–
Provision for credit impairment of other debt investment	–	–
Revaluation of fixed assets	–	–
Cash flows hedging reserve	–	–
Exchange differences arising from translation of foreign currency financial statements	–	–
Others	–	–

Item	Accumulated amount for the year	Amount for the corresponding period of last year
VII. Total comprehensive income	534,999,718.22	130,213,281.27
VIII. Earnings per share:	–	–
Basic earnings per share	–	–
Diluted earnings per share	–	–
Add: undistributed profit at the beginning of the year	139,719,503.05	113,362,698.51
Changes in accounting policies	–	–
Losses covered by surplus reserve	–	–
Other adjustment factors	–	–
IX. Distributable profit	674,719,221.27	243,575,979.78
Less: Appropriation of statutory surplus reserve	–	–
Appropriation for staff bonuses and benefit funds	–	–
Appropriation for reserve funds	–	–
Appropriation for company development funds	–	–
Others	–	–
X. Distributable profit attributable to investors	674,719,221.27	243,575,979.78
Preference shares dividends payable		
Appropriation of discretionary surplus reserve	–	–
Ordinary shares dividends payable	–	–
Ordinary shares dividends converted to equity	–	–
Others	–	(82,210,684.93)
XI. Undistributed profit	674,719,221.27	161,365,294.85

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
STATEMENT OF CASH FLOWS IN ACCORDANCE WITH THE PRC STANDARDS
SEPTEMBER 2023

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Cash flows from operating activities:		
Cash received from the sales of goods and the rendering of services	–	–
Refund of taxes and levies	12,089,045.26	232,321.35
Cash received relating to other operating activities	168,372,772.85	2,886,711.89
Sub-total of cash inflows from operating activities	180,461,818.11	3,119,033.24
Cash paid for goods purchased and services received	–	185,159.87
Cash paid to and for employees	93,004,397.01	85,741,864.83
Payments of all types of taxes	4,020,147.36	24,476,799.66
Cash payments relating to other operating activities	146,534,494.90	80,342,412.27
Sub-total of cash outflows from operating activities	243,559,039.27	190,746,236.63
Net cash flow from operating activities	(63,097,221.16)	(187,627,203.39)
II. Cash Flow From Investing Activities:		
Cash received from investment recovery	12,859,000,000.09	10,077,000,000.00
Cash received from returns on investments	677,926,063.93	693,519,101.19
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	2,163.00	–
Net cash received from disposals of subsidiaries and other operating units	–	–
Cash received relating to other investing activities	–	
Sub-total of cash inflows from investing activities	13,536,928,227.02	10,770,519,101.19

Item	Accumulated amount for the year	Amount for the corresponding period of last year
Cash paid to acquire fixed assets, intangible assets and other long-term assets	–	245,279.37
Cash paid for investments	13,023,660,000.00	9,298,832,600.00
Net cash paid for acquisition of subsidiaries and other operational units	–	–
Cash payments relating to other investing activities	–	–
Sub-total of cash outflows from investing activities	13,023,660,000.00	9,299,077,879.37
Net cash flow from investing activities	513,268,227.02	1,471,441,221.82
III. Cash flow from financing activities:		
Cash received from capital contribution	–	–
Including: Cash received by subsidiaries from investments of minority shareholders		
Cash received from borrowings	7,600,000,000.00	1,000,000,000.00
Cash received from issuance of bonds	–	2,000,000,000.00
Cash payments relating to other financing activities	2,779,976,586.48	2,682,972,507.50
Sub-total of cash inflows from financing activities	10,379,976,586.48	5,682,972,507.50
Cash payments for debts settlement	8,389,525,000.00	4,920,195,000.00
Cash payments for distribution of dividends, profits, or interest expenses	295,200,114.84	174,014,519.99
Including: Dividends and profits paid by subsidiaries to minority shareholders	–	–
Cash payments relating to other financing activities	2,491,185,729.23	2,379,593,206.27
Sub-total of cash outflows from financing activities	11,175,910,844.07	7,473,802,726.26
Net cash flow from financing activities	(795,934,257.59)	(1,790,830,218.76)
IV. Effect of foreign exchange rate changes on cash and cash equivalents	49.99	152.27
V. Net increase in cash and cash equivalents	(345,763,201.74)	(507,016,048.06)
Add: Opening balance of cash and cash equivalent	707,909,890.75	1,993,194,927.07
VI. Closing balance of cash and cash equivalents	362,146,689.01	1,486,178,879.01

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
(CONSOLIDATED) BALANCE SHEET IN ACCORDANCE WITH
THE PRC STANDARDS SEPTEMBER 2023

Adjusted to denominated currency

Unit: RMB1

Item	Closing balance	Opening Balance	Item	Closing balance	Opening Balance
Current assets:			Current liabilities:		
Monetary fund	28,807,965,925.21	21,460,236,350.26	Short-term borrowings	52,716,902,793.32	34,043,085,357.69
Held-for-trading financial assets	7,879,988,802.69	7,507,282,064.09	Held-for-trading financial liabilities	-	-
Derivative financial assets	-	-	Notes payable and accounts payable	57,658,274,212.27	48,931,715,633.97
Notes receivable	802,218,927.90	1,282,351,620.85	Including: Notes payable	14,281,931,764.91	13,235,861,940.44
Accounts receivable	78,445,159,866.10	59,752,772,739.51	Accounts payable	43,376,342,447.36	35,695,853,693.53
Financing receivables	27,616,809,577.61	23,791,412,577.67	Receipts in advance	769,297.57	-
Prepayment	5,675,017,017.74	4,944,535,854.76	Contract liabilities	5,030,134,890.76	3,537,167,833.02
Other receivables	4,774,313,313.70	4,963,029,014.18	Staff remuneration payable	2,694,110,580.81	2,865,645,825.32
Including: Interest receivable	1,239,378.73	357,405.21	Including: Wages payable	876,462,908.26	837,252,195.56
Dividends receivable	0.00	-	Benefits payable	112,707.71	-
Inventory	33,225,760,462.19	26,512,656,200.39	Taxation payable	1,527,926,404.01	1,693,928,606.44
Including: Raw materials	2,936,910,145.62	2,001,565,703.09	Including: Tax payable	1,383,981,991.11	1,544,713,458.18
Goods in stock (finished products)	27,750,433,928.09	22,046,761,578.67	Other payables	27,300,347,806.93	33,920,717,774.06
Contract assets	5,122,206.37	20,902,554.50	Including: Interest payable	80,981,760.77	19,660,293.28
Assets held for sale	45,537,620.87	45,537,620.87	Dividends payable	4,720,124,246.49	4,742,559,196.26
Non-current assets due within one year	399,069,074.89	230,474,654.69	Insurance contract liabilities	-	-
Other current assets	1,061,623,516.03	949,308,138.08	Liabilities held for sale	-	-
			Non-current liabilities due within one year	3,339,371,448.47	2,425,355,671.25
			Other current liabilities	458,190,596.06	680,314,002.07
Total current assets	188,738,586,311.30	151,460,499,389.85	Total current liabilities	150,726,028,030.20	128,097,930,703.82
Non-current assets:			Non-current liabilities:		
Other debt investments	(0.25)	-	Long-term borrowings	9,091,419,738.74	4,541,902,620.38
Debt investments	-	-	Bonds payable	6,523,663,920.37	4,500,000,000.00
Long-term receivables	710,977,497.70	848,639,562.04	Long-term payables	228,510,996.27	202,670,546.43
Other equity instruments investments	79,516,350.97	-	Including: Long-term payables	8,112,552.08	4,339,529.35
Long-term equity investments	5,262,466,551.06	5,017,241,596.34	Special payables	220,398,444.19	198,331,017.08
Investment properties	317,767,450.45	276,177,811.18	Long-term employee remuneration payable	852,146,339.29	828,947,832.23
Other non-current financial assets	874,639,650.46	711,830,602.64	△Deferred revenue	1,003,534,553.75	775,139,183.18
Fixed assets	16,935,754,708.22	14,625,213,855.41	Estimated liabilities	36,359,957.85	25,591,135.89
Including: Disposal of fixed assets	7,137,161.52	6,954,460.97	Deferred income tax liabilities	1,711,777,197.08	1,477,912,561.45
Right-of-use assets	1,242,997,325.75	1,187,149,842.15	Lease liabilities	914,667,962.20	760,857,575.63
Construction in progress	2,328,714,828.33	2,007,929,961.98	Other non-current liabilities	40,306,811.03	973,637.93
Including: Construction materials	-	-	Including: Special reserve	-	-
Biological assets for production	12,065,366.87	14,124,727.44	Total non-current liabilities	20,402,387,476.58	13,113,995,093.12
Oil and gas assets	-	-	Total liabilities	171,128,415,506.78	141,211,925,796.94
Intangible assets	10,645,725,518.78	9,608,588,725.17	Owners' equity (or shareholders' equity):		
Including: Land use right	3,694,499,400.92	3,119,279,490.25	Paid-in capital (equity)	15,000,000,000.00	15,000,000,000.00
Development expenses	1,505,678,426.61	1,187,653,041.05	State-owned capital		
Goodwill	21,595,622,350.68	20,409,178,475.23	Collective capital		
Long-term deferred expenses	413,951,824.20	382,724,511.98	Legal person capital	15,000,000,000.00	15,000,000,000.00
Deferred income tax assets	1,788,624,213.68	1,403,146,719.07	Including: State-owned legal person capital	15,000,000,000.00	15,000,000,000.00
Other non-current assets	656,621,102.51	3,200,414,708.64	Collectively-owned legal person capital		
Including: Contract assets	157,433,419.91	144,562,622.12	Individual's capital		
			Foreign capital		
			Other equity instruments	-	-
			Capital surplus	976,526,770.38	684,984,441.90
			Less: treasury shares	(13,592,358.82)	-
			Other comprehensive income	54,641,059.99	51,232,170.86
			Including: Differences on translation of foreign currency statements	46,835,095.69	43,412,428.77
			Surplus reserves	585,301,471.54	597,938,830.75
			Special reserves	3,655,636.33	2,056,429.35
Total non-current assets	64,371,123,166.02	60,880,014,140.32	Undistributed profits	14,619,403,506.24	11,944,432,635.87
			Total equity attributable to owners of the parent company	31,253,120,803.30	28,280,644,508.73
			△Minority interests	50,728,173,167.31	42,847,943,224.50
			Total owners' equity	81,981,293,970.61	71,128,587,733.23
Total assets	253,109,709,477.32	212,340,513,530.17	Total liabilities and owners' equity	253,109,709,477.39	212,340,513,530.17

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
(CONSOLIDATED) STATEMENT OF PROFIT OR LOSS IN ACCORDANCE WITH
THE PRC STANDARDS SEPTEMBER 2023

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Operating revenue	182,208,781,364.61	161,807,092,060.21
Including: Revenue from principal businesses	180,689,566,468.75	160,598,192,918.67
Revenue from other businesses	1,519,214,895.87	1,208,899,141.54
II. Operating costs	152,459,837,301.92	136,100,866,085.05
Including: Costs for principal businesses	151,636,656,435.70	135,437,674,608.71
Costs for other businesses	823,180,866.21	663,191,476.33
Tax and surcharge	752,420,128.11	684,654,466.23
Selling expenses	13,524,771,891.98	11,463,201,664.56
Management expenses	4,266,838,903.18	3,657,881,923.42
Including: Entertainment expenses	60,826,190.69	52,306,653.91
Research and development expenses	1,294,182,804.44	1,080,019,164.28
Finance costs	1,469,379,871.26	1,844,064,688.41
Including: Interest expenses	1,812,572,100.21	1,656,389,748.34
Interest income	319,361,323.15	336,719,666.78
Net Loss from exchange (net gain is represented by “—”)	(110,959,738.21)	453,287,184.65
Other revenue	331,984,070.31	293,731,661.49
Gain from investment (loss is represented by “—”)	195,889,415.99	576,089,473.42
Including: Gains from investment in associates and joint ventures	306,787,014.46	273,596,470.65

Item	Accumulated amount for the year	Amount for the corresponding period of last year
Gain from derecognition of financial assets at amortised costs	–	–
Net gains from hedging exposure (loss is represented by “–”)	–	–
Add: gains from changes in fair values (loss is represented by “–”)	97,475,814.08	87,168,621.36
Impairment losses of assets	152,875,675.37	87,043,296.21
Loss on credit impairment	474,299,520.34	618,948,213.07
Gains from disposal of assets	38,919,687.08	11,613,194.41
III. Operating profits (loss is represented by “–”)	8,478,444,255.48	7,239,015,509.66
Add: Non-operating income	112,137,958.58	72,183,448.64
Including: Gains from exchanging non-monetary assets	–	–
Government subsidies	6,197.46	1,446,593.69
Less: Non-operating expenses	105,648,734.43	56,909,043.43
Including: Loss on exchanging non-monetary assets	–	–
IV. Total profits (total loss is represented by “–”)	8,484,933,479.64	7,254,289,914.86
Less: Income tax expenses	1,749,327,366.40	1,611,527,481.03
V. Net profits (net loss is represented by “–”)	6,735,606,113.23	5,642,762,433.83
Including: Net gains of the absorbed party before business combination under common control		
Net profits attributable to the owners of the parent company	2,670,648,512.40	2,143,375,079.58
* Gains and losses of minority interests	3,969,107,600.83	3,499,387,354.25
Profit attributable to holders of perpetual capital instruments	95,850,000.00	–

Item	Accumulated amount for the year	Amount for the corresponding period of last year
VI. Other comprehensive income, net of tax	4,687,685.11	36,421,109.39
(I) Other comprehensive income that cannot be reclassified into profit and loss	(12,725.47)	(85,952.34)
Changes arising from remeasurement of defined benefit plan	–	(70,000.00)
Other comprehensive income that cannot be reclassified into profit or loss under the equity method	(12,725.47)	(15,952.34)
Changes in fair value of other equity instrument investments	–	–
(II) Other comprehensive income that may be reclassified to profit or loss	4,700,410.58	36,507,061.73
Other comprehensive income that may be reclassified to profit or loss under equity method	1,529.94	(6,049.88)
Change in fair value of other debt investments	–	–
Amount included in other comprehensive income on reclassification of financial assets	–	–
Provision for credit impairment of other debt investment	–	–
Revaluation of fixed assets	–	(116,949.75)
Cash flows hedging reserve	–	–
Exchange differences arising from translation of foreign currency financial statements	4,698,880.64	36,488,953.34
Others	–	141,108.02
VII. Total comprehensive income	6,740,293,798.35	5,679,183,543.22

Item	Accumulated amount for the year	Amount for the corresponding period of last year
VIII. Earnings per share:	–	–
Basic earnings per share	–	–
Diluted earnings per share	–	–
Add: undistributed profit at the beginning of the year	11,944,432,635.95	11,486,890,605.67
Changes in accounting policies	–	0.00
Losses covered by surplus reserve	–	–
Other adjustment factors	(3,557.37)	–
IX. Distributable profit	14,615,077,590.98	13,630,265,685.25
Less: Appropriation of statutory surplus reserve	2,875,835.49	–
Appropriation for staff bonuses and benefit funds	–	–
Appropriation for reserve funds	–	–
Appropriation for company development funds	–	–
Others	–	–
X. Distributable profit attributable to investors	14,617,953,426.47	13,630,265,685.25
Preference shares dividends payable		
Appropriation of discretionary surplus reserve	–	–
Ordinary shares dividends payable	(0.00)	54.66
Ordinary shares dividends converted to equity	-	-
Others	1,450,079.78	(82,210,684.93)
XI. Undistributed profit	14,619,403,506.24	13,548,055,054.98

**CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
(CONSOLIDATED) STATEMENT OF CASH FLOWS IN ACCORDANCE WITH
THE PRC STANDARDS SEPTEMBER 2023**

Adjusted to denominated currency

Unit: RMB1

Item	Accumulated amount for the year	Amount for the corresponding period of last year
I. Cash flows from operating activities:		
Cash received from the sales of goods and the rendering of services	182,078,449,278.54	160,165,852,825.80
Refund of taxes and levies	306,751,175.07	127,079,474.21
Cash received relating to other operating activities	9,813,095,161.70	8,928,900,243.72
Sub-total of cash inflows from operating activities	192,198,295,615.32	169,221,832,543.73
Cash paid for goods purchased and services received	155,379,991,293.72	136,407,098,879.96
Cash paid to and for employees	9,078,473,077.15	7,798,284,315.34
Payments of all types of taxes	6,973,154,353.65	5,977,785,623.90
Cash payments relating to other operating activities	19,741,298,693.04	17,685,013,825.00
Sub-total of cash outflows from operating activities	191,172,917,417.56	167,868,182,644.20
Net cash flow from operating activities	1,025,378,197.76	1,353,649,899.53
II. Cash Flow From Investing Activities:		
Cash received from investment recovery	13,773,905,849.50	21,280,857,852.21
Cash received from returns on investments	274,191,860.58	374,121,786.91
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	52,180,404.83	11,972,596.72
Net cash received from disposals of subsidiaries and other operating units	0.00	421,418,127.34
Cash received relating to other investing activities	1,290,706,654.69	12,803,185.79
Sub-total of cash inflows from investing activities	15,390,984,769.60	22,101,173,548.97

Item	Accumulated amount for the year	Amount for the corresponding period of last year
Cash paid to acquire fixed assets, intangible assets and other long-term assets	1,662,355,824.77	1,745,892,242.25
Cash paid for investments	14,827,527,320.53	21,626,623,576.98
Net cash paid for acquisition of subsidiaries and other operational units	517,837,874.27	613,357,254.24
Cash payments relating to other investing activities	7,891,081.43	22,140,000.00
Sub-total of cash outflows from investing activities	17,015,612,101.00	24,008,013,073.47
Net cash flow from investing activities	(1,624,627,331.39)	(1,906,839,524.50)
III. Cash flow from financing activities:		
Cash received from capital contribution	325,861,772.24	279,424,680.00
Including: Cash received by subsidiaries from investments of minority shareholders		
Cash received from borrowings	66,174,104,587.68	55,507,536,306.34
Cash received from issuance of bonds	2,000,000,000.00	2,000,000,000.00
Cash payments relating to other financing activities	13,647,726,639.29	14,771,243,118.76
Sub-total of cash inflows from financing activities	82,147,692,999.21	72,558,204,105.10
Cash payments for debts settlement	57,809,776,244.26	51,048,528,636.02
Cash payments for distribution of dividends, profits, or interest expenses	3,405,190,674.46	2,859,130,164.48
Including: Dividends and profits paid by subsidiaries to minority shareholders	101,541,656.48	44,245,898.37
Cash payments relating to other financing activities	14,901,553,865.54	16,897,108,293.18
Sub-total of cash outflows from financing activities	76,116,520,784.26	70,804,767,093.68
Net cash flow from financing activities	6,031,172,214.95	1,753,437,011.42
IV. Effect of foreign exchange rate changes on cash and cash equivalents	10,096,974.19	23,022,571.82
V. Net increase in cash and cash equivalents	5,442,020,055.50	1,223,269,958.27
Add: Opening balance of cash and cash equivalent	15,139,972,048.18	14,321,098,931.84
VI. Closing balance of cash and cash equivalents	20,581,992,103.68	15,544,368,890.11